BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 26830377)

  • 1. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study.
    Yock TI; Yeap BY; Ebb DH; Weyman E; Eaton BR; Sherry NA; Jones RM; MacDonald SM; Pulsifer MB; Lavally B; Abrams AN; Huang MS; Marcus KJ; Tarbell NJ
    Lancet Oncol; 2016 Mar; 17(3):287-298. PubMed ID: 26830377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late toxicity following craniospinal radiation for early-stage medulloblastoma.
    Christopherson KM; Rotondo RL; Bradley JA; Pincus DW; Wynn TT; Fort JA; Morris CG; Mendenhall NP; Marcus RB; Indelicato DJ
    Acta Oncol; 2014 Apr; 53(4):471-80. PubMed ID: 24564687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma.
    Polkinghorn WR; Dunkel IJ; Souweidane MM; Khakoo Y; Lyden DC; Gilheeney SW; Becher OJ; Budnick AS; Wolden SL
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e15-20. PubMed ID: 21481547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.
    Kortmann RD; Kühl J; Timmermann B; Mittler U; Urban C; Budach V; Richter E; Willich N; Flentje M; Berthold F; Slavc I; Wolff J; Meisner C; Wiestler O; Sörensen N; Warmuth-Metz M; Bamberg M
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):269-79. PubMed ID: 10661332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.
    Robinson GW; Rudneva VA; Buchhalter I; Billups CA; Waszak SM; Smith KS; Bowers DC; Bendel A; Fisher PG; Partap S; Crawford JR; Hassall T; Indelicato DJ; Boop F; Klimo P; Sabin ND; Patay Z; Merchant TE; Stewart CF; Orr BA; Korbel JO; Jones DTW; Sharma T; Lichter P; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Sanders RP; Onar-Thomas A; Ellison DW; Gajjar A; Northcott PA
    Lancet Oncol; 2018 Jun; 19(6):768-784. PubMed ID: 29778738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes Among Children With Standard-Risk Medulloblastoma Treated With Proton and Photon Radiation Therapy: A Comparison of Disease Control and Overall Survival.
    Eaton BR; Esiashvili N; Kim S; Weyman EA; Thornton LT; Mazewski C; MacDonald T; Ebb D; MacDonald SM; Tarbell NJ; Yock TI
    Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):133-138. PubMed ID: 26700707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma.
    Kahalley LS; Peterson R; Ris MD; Janzen L; Okcu MF; Grosshans DR; Ramaswamy V; Paulino AC; Hodgson D; Mahajan A; Tsang DS; Laperriere N; Whitehead WE; Dauser RC; Taylor MD; Conklin HM; Chintagumpala M; Bouffet E; Mabbott D
    J Clin Oncol; 2020 Feb; 38(5):454-461. PubMed ID: 31774710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review.
    Vieira WA; Weltman E; Chen MJ; da Silva NS; Cappellano AM; Pereira LD; Gonçalves MI; Ferrigno R; Hanriot RM; Nadalin W; Odone Filho V; Petrilli AS
    Radiat Oncol; 2014 Jul; 9():158. PubMed ID: 25041714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton radiation therapy for pediatric medulloblastoma and supratentorial primitive neuroectodermal tumors: outcomes for very young children treated with upfront chemotherapy.
    Jimenez RB; Sethi R; Depauw N; Pulsifer MB; Adams J; McBride SM; Ebb D; Fullerton BC; Tarbell NJ; Yock TI; Macdonald SM
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):120-6. PubMed ID: 23790826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ototoxicity and cochlear sparing in children with medulloblastoma: Proton vs. photon radiotherapy.
    Paulino AC; Mahajan A; Ye R; Grosshans DR; Fatih Okcu M; Su J; McAleer MF; McGovern S; Mangona VA; Chintagumpala M
    Radiother Oncol; 2018 Jul; 128(1):128-132. PubMed ID: 29373195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pediatric average-risk medulloblastoma using craniospinal irradiation less than 2500 cGy and chemotherapy: single center experience in Korea.
    Yoon JH; Park KD; Kang HJ; Kim H; Lee JW; Kim SK; Wang KC; Park SH; Kim IH; Shin HY
    World J Pediatr; 2017 Aug; 13(4):367-373. PubMed ID: 28550392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the radiation therapy dose prescription for pediatric medulloblastoma: minimizing the life years lost attributable to failure to control the disease and late complication risk.
    Brodin NP; Vogelius IR; Björk-Eriksson T; Munck Af Rosenschöld P; Maraldo MV; Aznar MC; Specht L; Bentzen SM
    Acta Oncol; 2014 Apr; 53(4):462-70. PubMed ID: 24274390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising survival rate but high incidence of treatment-related mortality after reduced-dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma.
    Lee JW; Lim DH; Sung KW; Cho HW; Ju HY; Hyun JK; Yoo KH; Koo HH; Suh YL; Joung YS; Shin HJ
    Cancer Med; 2020 Aug; 9(16):5807-5818. PubMed ID: 32608158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma.
    Liu KX; Ioakeim-Ioannidou M; Susko MS; Rao AD; Yeap BY; Snijders AM; Ladra MM; Vogel J; Zaslowe-Dude C; Marcus KJ; Yock TI; Grassberger C; Braunstein SE; Haas-Kogan DA; Terezakis SA; MacDonald SM
    Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):726-735. PubMed ID: 33243479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
    Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-volume tumor-bed boost is not associated with inferior local control and survival outcomes in high-risk medulloblastoma.
    Tian S; Sudmeier LJ; Zhang C; Madden NA; Buchwald ZS; Shu HG; Curran WJ; Eaton BR; Esiashvili N
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28027. PubMed ID: 31571408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of adult medulloblastoma patients treated with radiotherapy.
    De B; Beal K; De Braganca KC; Souweidane MM; Dunkel IJ; Khakoo Y; Gilheeney SW; DeAngelis LM; Menzel P; Patel SH; Wolden SL
    J Neurooncol; 2018 Jan; 136(1):95-104. PubMed ID: 29019042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.